Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00474539
Last updated date
ABOUT THIS STUDY
The purpose of this study is to assess the safety, tolerability and immunogenicity of a
13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
concomitantly with routine paediatric vaccinations in Spain.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Pneumococcal Vaccines
Sex
Females and Males
Age
42-98 days
Inclusion Criteria
Show details
- Healthy 2-month-old infants
- Available for the entire study period
Exclusion Criteria
Show details
- Previous vaccination with any vaccine before the start of the study
- Known contraindication to vaccination
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Pneumococcal VaccinesStudy Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548
- Chandler, Arizona
- Pembroke Pines, Florida
- Boise, Idaho
- Raleigh, North Carolina
- Cincinnati, Ohio
- Bristol, Tennessee
ALL GENDERS
60 Years+
years
MULTIPLE SITES
Pneumococcal Vaccines13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
NCT01964716
- Fajara, The Gambia, West Africa
- Ksmd, The Gambia
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal VaccinesStudy Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00474539
- Almeria,
- Almeria,
- Almeria,
- Barcelona,
- Barcelona,
- Coruna,
- Coruna,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Malaga,
- Malaga,
- Ourense,
- Pamplona,
- Santiago de Compostela,
- Seville,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Vigo,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal VaccinesStudy Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
NCT00708682
- Guadalajara, Jalisco
- Morelia, Michoacan
- Cuernavaca, Morelos
- Monterrey, Nuevo Leon
- Merida, Yucatan
- Distrio Federal,
- Distrio Federal,
- Oaxaca,
- Puebla,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants | ||||||
Official Title ICMJE | A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain | ||||||
Brief Summary | The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Spain. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention | ||||||
Condition ICMJE | Vaccines, Pneumococcal | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinón-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 449 | ||||||
Original Estimated Enrollment ICMJE | 440 | ||||||
Actual Study Completion Date ICMJE | March 2009 | ||||||
Actual Primary Completion Date | March 2009 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 42 Days to 98 Days (Child) | ||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Spain | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT00474539 | ||||||
Other Study ID Numbers ICMJE | 6096A1-3007 | ||||||
Has Data Monitoring Committee | Not Provided | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Responsible Party | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
Verification Date | January 2013 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |